Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Apr 30, 2025 · Filed Apr 30, 2025
A Zentalis Pharmaceuticals director paid $29K out of pocket for Zentalis Pharmaceuticals shares. Shares held went up 8% with this purchase.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$29,373
Shares × reported transaction price
$25K–$100K
+8.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
35 days after results of Mar 26, 2025, 14 days before results of May 14, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
None found in footnotes
Only flagged when a footnote says so; never inferred
Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Feb 6, 2025 · filed 6 days later
Zentalis Pharmaceuticals's Chief Medical Officer paid $46K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month. Shares held went up 120% with this purchase.
Andrea Paul (Chief Legal Officer) sold ~$23K of Zentalis Pharmaceuticals
Automatic sale